Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

SCLX US Equity

Scilex Holding CoHealth Care · Biological Products, (No Diagnostic Substances) · CIK 1820190 · FY ends Dec 31
$5.73
-0.07 (-1.21%)
USD · as of 2026-08-21 · marketstack
2 registered studies · 0 active

Studies where SCLX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

2 interventional

Held by 2 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Enhanced Safety Laser Hair Removal SystemNCT00441948Hair reduction as counted 1-3 months after each treatment session, depending on the treated area.Non-randomized · Single-masked · TreatmentNot applicableUnknown statusDevice: PeterioHirsutism, Hypertrichosis102007-03-01
Enhanced Safety Aesthetic Laser SystemNCT00495443Hair, vascular lesions and wrinkles reduction as counted 1-3 months after each treatment session, depending on the treated area.Non-randomized · Single-masked · TreatmentNot applicableUnknown statusDevice: PeterioHirsutism, Hypertrichosis, Telangiectases, Rhytides252007-07-03

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-21